Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors
maanantai 20. huhtikuuta 2020 päivittänyt: Caicun Zhou, Shanghai Pulmonary Hospital, Shanghai, China
A Cohort Study to Evaluate the Impact of Inactivated Trivalent Influenza Vaccine on the Immunogenicity, Safety and Survival of Non-small Cell Lung Cancer Patients Receiving PD-1 / PD-L1 Inhibitors
This project is to assess the immunogenicity, safety and overall survival impact of intramuscular injection of trivalent influenza vaccine in non-small cell lung cancer (NSCLC) patients with PD-1/PD-L1 inhibitor treatment.
Tutkimuksen yleiskatsaus
Tila
Ei vielä rekrytointia
Interventio / Hoito
Yksityiskohtainen kuvaus
Lung cancer is one of the most prevalent cancers in the world. Among them, non-small cell lung cancer (NSCLC) accounts for about 85%. Immune checkpoint inhibitors such as programmed death 1(PD-1) and PD-L1 are new treatments for NSCLC. About 290,000 to 650,000 people die from respiratory illnesses caused by seasonal flu all over the world. Cancer patients are one of the high-risk groups of influenza. Although the United States, Britain, Australia have issued guidelines recommending that cancer patients be vaccinated against influenza every year, due to concerns about the immune effect and safety of flu vaccination for cancer patients, multiple countries including China have not included cancer patients into priority influenza vaccination populations. Therefore, how to further prove the immunogenicity and safety of influenza vaccine in NSCLC patients is the key to promote influenza vaccines in NSCLC patients.
This study will recruit 130 patients with NSCLC who have been treated with PD-1 / PD-L1 inhibitors for 6 months or more and 30 healthy participants. Among them, 100 NSCLC patients and 30 healthy participants will be intramuscularly inactivated with a trivalent influenza vaccine during the influenza seasons 2020-21 and 2021-22. Vaccinated participants' peripheral blood samples were collected at day0, 12 hours, day1, 2, 7, 21, 30, 60 and 6 months after vaccination. The influenza specific antibody titers, inflammatory chemokines and cytokines, antibody-dependent cellular cytotoxicity (ADCC) activity, T lymphocytes activity and the proportions of different T cells subgroups will be measured to evaluate the participants' immune response to the vaccine. In addition, for the subjects receiving the vaccine, the study will also group by age to compare the differences in immune effects between subjects aged 18-65 and subjects over 65.
At last, this project will compare immune-related adverse events (irAEs) that occurred after receiving PD-1 / PD-L1 inhibitor therapy and survival time between NSCLC patients who receive influenza vaccine and those who do not receive influenza vaccine.
Opintotyyppi
Havainnollistava
Ilmoittautuminen (Odotettu)
160
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskeluyhteys
- Nimi: Yayi He
- Puhelinnumero: 8613818828623
- Sähköposti: 2250601@qq.com
Opiskelupaikat
-
-
Hong Kong
-
Hong Kong, Hong Kong, Kiina
- School of Public Health, Li Ka Shing Faculty of Medicine, University of Hong Kong
-
Ottaa yhteyttä:
- Lit Man Leo Poon, PhD.
- Puhelinnumero: 852-3917 9943
- Sähköposti: llmpoon@hkucc.hku.hk
-
-
Shanghai
-
Shanghai, Shanghai, Kiina, 200433
- Shanghai Pulmonary Hospital
-
Ottaa yhteyttä:
- Yayi He
- Puhelinnumero: 8613818828623
- Sähköposti: 2250601@qq.com
-
Päätutkija:
- Yayi He, PhD, MD
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
18 vuotta - 75 vuotta (Aikuinen, Vanhempi Aikuinen)
Hyväksyy terveitä vapaaehtoisia
Ei
Sukupuolet, jotka voivat opiskella
Kaikki
Näytteenottomenetelmä
Todennäköisyysnäyte
Tutkimusväestö
NSCLC patients receiving PD-1/PD-L1 inhibitors during this project
Kuvaus
Inclusion Criteria:
- NSCLC patients were diagnosed with clear pathological classification and receive PD-1 / PD-L1 inhibitor treatment during this project.
- NSCLC patients have the exact start and end time of PD-1 / PD-L1 inhibitor and / or the vaccination time and follow-up information.
- The healthy participants are not in an immunosuppressive state, such as cancer, HIV, autoimmune diseases, and long-term use of immunosuppressive drugs.
- The healthy participants have exact vaccination time.
- All participants have complete clinical and laboratory diagnostic data.
- All participants are 18-75 years, regardless of gender.
- All participants have agreed and signed the consent form before enrollment.
Exclusion Criteria:
- Patients with unclear diagnosis of lung cancer were excluded.
- Patients with incomplete clinical data or incomplete follow-up records.
- Patients without signed informed consent.
- Patient has received blood transfusion within three months.
- Patients with HIV, Hepatitis B and Hepatitis C infections.
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: Kohortti
- Aikanäkymät: Tulevaisuuden
Kohortit ja interventiot
Ryhmä/Kohortti |
Interventio / Hoito |
|---|---|
|
Vaccinated NSCLC group
This group contains 100 NSCLC patients receiving PD-1/PD-L1 inhibitors for more than 6 months, who will be intramuscularly injected one dose of inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).
|
Including nivolumab, pembrolizumab, atezolizumab, and durvalumab, et al.
Muut nimet:
Including two type A viruses, H1N1 and H3N2, and one type B virus, B/Brisbane.
Muut nimet:
|
|
Vaccinated Health group
This group contains 30 healthy participants without immunosuppressive diseases, who will be intramuscularly injected one dose of inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).
|
Including two type A viruses, H1N1 and H3N2, and one type B virus, B/Brisbane.
Muut nimet:
|
|
Unvaccinated NSCLC group
This group contains 30 NSCLC patients receiving PD-1/PD-L1 inhibitors for more than 6 months without intramuscular injection of any inactivated trivalent influenza vaccine in influenza seasons 2020-21 or 2021-22 (November-May).
|
Including nivolumab, pembrolizumab, atezolizumab, and durvalumab, et al.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Titers of anti-nucleoprotein(NP) or anti-hemagglutinin(HA) antibody (IgG and IgM)
Aikaikkuna: Day 0 after vaccination
|
The titers of anti-HA IgG and IgM antibodies ,and anti-NP IgG and IgM antibodies are measured by enzyme linked immunosorbent assay (ELISA).
|
Day 0 after vaccination
|
|
Titers of anti-nucleoprotein(NP) or anti-hemagglutinin(HA) antibody (IgG and IgM)
Aikaikkuna: Day 2 after vaccination
|
The titers of anti-HA IgG and IgM antibodies ,and anti-NP IgG and IgM antibodies are measured by enzyme linked immunosorbent assay (ELISA).
|
Day 2 after vaccination
|
|
Titers of anti-nucleoprotein(NP) or anti-hemagglutinin(HA) antibody (IgG and IgM)
Aikaikkuna: Day 7 after vaccination
|
The titers of anti-HA IgG and IgM antibodies ,and anti-NP IgG and IgM antibodies are measured by enzyme linked immunosorbent assay (ELISA).
|
Day 7 after vaccination
|
|
Titers of anti-nucleoprotein(NP) or anti-hemagglutinin(HA) antibody (IgG and IgM)
Aikaikkuna: Day 21 after vaccination
|
The titers of anti-HA IgG and IgM antibodies ,and anti-NP IgG and IgM antibodies are measured by enzyme linked immunosorbent assay (ELISA).
|
Day 21 after vaccination
|
|
Titers of anti-nucleoprotein(NP) or anti-hemagglutinin(HA) antibody (IgG and IgM)
Aikaikkuna: Day 30 after vaccination
|
The titers of anti-HA IgG and IgM antibodies ,and anti-NP IgG and IgM antibodies are measured by enzyme linked immunosorbent assay (ELISA).
|
Day 30 after vaccination
|
|
Titer of neutralization antibody
Aikaikkuna: Day 0 after vaccination
|
Titer of neutralization antibody is measured by neutralization test.
|
Day 0 after vaccination
|
|
Titer of neutralization antibody
Aikaikkuna: Day 21 after vaccination
|
Titer of neutralization antibody is measured by neutralization test.
|
Day 21 after vaccination
|
|
Titer of neutralization antibody
Aikaikkuna: Day 30 after vaccination
|
Titer of neutralization antibody is measured by neutralization test.
|
Day 30 after vaccination
|
|
Titer of neutralization antibody
Aikaikkuna: Day 60 after vaccination
|
Titer of neutralization antibody is measured by neutralization test.
|
Day 60 after vaccination
|
|
Titer of neutralization antibody
Aikaikkuna: Month 6 after vaccination
|
Titer of neutralization antibody is measured by neutralization test.
|
Month 6 after vaccination
|
|
Multiple chemokine and cytokine levels in peripheral blood
Aikaikkuna: Day 0 after vaccination
|
IFN-γ, IL-1β, IL-2,IL-3,IL-4,IL-5,IL-6,IL-8 (CXCL8),IL-9,IL-10,IL-11,IL-12,IL-13,GM-CSF,TNF-α, IP-10 (CXCL10), MCP-1 (CCL2), and TARC (CCL17) in peripheral blood are measured by cytometry bead assay.
|
Day 0 after vaccination
|
|
Multiple chemokine and cytokine levels in peripheral blood
Aikaikkuna: 12 hours after vaccination
|
IFN-γ, IL-1β, IL-2,IL-3,IL-4,IL-5,IL-6,IL-8 (CXCL8),IL-9,IL-10,IL-11,IL-12,IL-13,GM-CSF,TNF-α, IP-10 (CXCL10), MCP-1 (CCL2), and TARC (CCL17) in peripheral blood are measured by cytometry bead assay.
|
12 hours after vaccination
|
|
Multiple chemokine and cytokine levels in peripheral blood
Aikaikkuna: Day 1 after vaccination
|
IFN-γ, IL-1β, IL-2,IL-3,IL-4,IL-5,IL-6,IL-8 (CXCL8),IL-9,IL-10,IL-11,IL-12,IL-13,GM-CSF,TNF-α, IP-10 (CXCL10), MCP-1 (CCL2), and TARC (CCL17) in peripheral blood are measured by cytometry bead assay.
|
Day 1 after vaccination
|
|
Multiple chemokine and cytokine levels in peripheral blood
Aikaikkuna: Day 2 after vaccination
|
IFN-γ, IL-1β, IL-2,IL-3,IL-4,IL-5,IL-6,IL-8 (CXCL8),IL-9,IL-10,IL-11,IL-12,IL-13,GM-CSF,TNF-α, IP-10 (CXCL10), MCP-1 (CCL2), and TARC (CCL17) in peripheral blood are measured by cytometry bead assay.
|
Day 2 after vaccination
|
|
The numbers and proportions of T lymphocyte subpopulations in peripheral blood
Aikaikkuna: Day 0 after vaccination
|
The numbers and proportions of CD4+ T cells, CD8+ T cells, naïve T cells and effector memory T cells in peripheral blood are measured by multiple flow cytometry.
|
Day 0 after vaccination
|
|
The numbers and proportions of T lymphocyte subpopulations in peripheral blood
Aikaikkuna: 12 hours after vaccination
|
The numbers and proportions of CD4+ T cells, CD8+ T cells, naïve T cells and effector memory T cells in peripheral blood are measured by multiple flow cytometry.
|
12 hours after vaccination
|
|
The numbers and proportions of T lymphocyte subpopulations in peripheral blood
Aikaikkuna: Day 1 after vaccination
|
The numbers and proportions of CD4+ T cells, CD8+ T cells, naïve T cells and effector memory T cells in peripheral blood are measured by multiple flow cytometry.
|
Day 1 after vaccination
|
|
The numbers and proportions of T lymphocyte subpopulations in peripheral blood
Aikaikkuna: Day 2 after vaccination
|
The numbers and proportions of CD4+ T cells, CD8+ T cells, naïve T cells and effector memory T cells in peripheral blood are measured by multiple flow cytometry.
|
Day 2 after vaccination
|
|
The numbers and proportions of T lymphocyte subpopulations in peripheral blood
Aikaikkuna: Day 7 after vaccination
|
The numbers and proportions of CD4+ T cells, CD8+ T cells, naïve T cells and effector memory T cells in peripheral blood are measured by multiple flow cytometry.
|
Day 7 after vaccination
|
|
The numbers and proportions of T lymphocyte subpopulations in peripheral blood
Aikaikkuna: Day 21 after vaccination
|
The numbers and proportions of CD4+ T cells, CD8+ T cells, naïve T cells and effector memory T cells in peripheral blood are measured by multiple flow cytometry.
|
Day 21 after vaccination
|
|
The numbers and proportions of T lymphocyte subpopulations in peripheral blood
Aikaikkuna: Day 30 after vaccination
|
The numbers and proportions of CD4+ T cells, CD8+ T cells, naïve T cells and effector memory T cells in peripheral blood are measured by multiple flow cytometry.
|
Day 30 after vaccination
|
|
The numbers and proportions of T lymphocyte subpopulations in peripheral blood
Aikaikkuna: Day 60 after vaccination
|
The numbers and proportions of CD4+ T cells, CD8+ T cells, naïve T cells and effector memory T cells in peripheral blood are measured by multiple flow cytometry.
|
Day 60 after vaccination
|
|
The numbers and proportions of T lymphocyte subpopulations in peripheral blood
Aikaikkuna: Month 6 after vaccination
|
The numbers and proportions of CD4+ T cells, CD8+ T cells, naïve T cells and effector memory T cells in peripheral blood are measured by multiple flow cytometry.
|
Month 6 after vaccination
|
|
Peripheral T cell activation and proliferation
Aikaikkuna: Day 0 after vaccination
|
The CD3, CD4, CD8 and CD69 expressions and cell count of peripheral T cells are measured by multiple flow cytometry upon carboxyfluorescein succinimidyl amino ester (CFSE) labeling and anti-CD3/28 beads activation.
|
Day 0 after vaccination
|
|
Peripheral T cell activation and proliferation
Aikaikkuna: Day 30 after vaccination
|
The CD3, CD4, CD8 and CD69 expressions and cell count of peripheral T cells are measured by multiple flow cytometry upon carboxyfluorescein succinimidyl amino ester (CFSE) labeling and anti-CD3/28 beads activation.
|
Day 30 after vaccination
|
|
Peripheral T cell activation and proliferation
Aikaikkuna: Day 60 after vaccination
|
The CD3, CD4, CD8 and CD69 expressions and cell count of peripheral T cells are measured by multiple flow cytometry upon carboxyfluorescein succinimidyl amino ester (CFSE) labeling and anti-CD3/28 beads activation.
|
Day 60 after vaccination
|
|
Peripheral T cell activation and proliferation
Aikaikkuna: Month 6 after vaccination
|
The CD3, CD4, CD8 and CD69 expressions and cell count of peripheral T cells are measured by multiple flow cytometry upon carboxyfluorescein succinimidyl amino ester (CFSE) labeling and anti-CD3/28 beads activation.
|
Month 6 after vaccination
|
|
Antibody-dependent cellular cytotoxicity (ADCC)
Aikaikkuna: Day 0 after vaccination
|
The ADCC activities of NK-92 cells cultured by the sera from vaccinated participants are measured by lactic acid dehydrogenase (LDH) release of A549 cells infected by H1N1 and H3N2.
|
Day 0 after vaccination
|
|
Antibody-dependent cellular cytotoxicity (ADCC)
Aikaikkuna: Day 30 after vaccination
|
The ADCC activities of NK-92 cells cultured by the sera collected from vaccinated participants are measured by lactic acid dehydrogenase (LDH) release of A549 cells infected by H1N1 and H3N2.
|
Day 30 after vaccination
|
|
Antibody-dependent cellular cytotoxicity (ADCC)
Aikaikkuna: Day 60 after vaccination
|
The ADCC activities of NK-92 cells cultured by the sera collected from vaccinated participants are measured by lactic acid dehydrogenase (LDH) release of A549 cells infected by H1N1 and H3N2.
|
Day 60 after vaccination
|
|
Antibody-dependent cellular cytotoxicity (ADCC)
Aikaikkuna: Month 6 after vaccination
|
The ADCC activities of NK-92 cells cultured by the sera collected from vaccinated participants are measured by lactic acid dehydrogenase (LDH) release of A549 cells infected by H1N1 and H3N2.
|
Month 6 after vaccination
|
|
Immune-related adverse events (irAEs)
Aikaikkuna: June 2020- June 2023
|
The performances and the grades of irAEs according to Common Terminology Criteria for Adverse Events 5.0 (CTCAE 5.0) and their correlation with vaccination.
|
June 2020- June 2023
|
|
Progression-free Survival (PFS)
Aikaikkuna: June 2020- June 2023 (3 year)
|
PFS is calculated as the time from from PD-1/PD-L1 inhibitor starting to the disease progression or the death from any cause.
|
June 2020- June 2023 (3 year)
|
|
Overall Survival (OS)
Aikaikkuna: June 2020- June 2023 (3 year)
|
OS is calculated as the time from PD-1/PD-L1 inhibitor starting to the death from any cause.
|
June 2020- June 2023 (3 year)
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Objective Response Rate (ORR)
Aikaikkuna: June 2020- June 2023 (3 year)
|
The proportion of patients whose tumors have shrunk to a certain amount and maintained for a certain period of time, including cases of complete response (CR) and partial response (PR) according to Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1).
|
June 2020- June 2023 (3 year)
|
|
Disease Control Rate (DCR)
Aikaikkuna: June 2020- June 2023 (3 year)
|
The proportion of patients achieve CR or PR or stable disease (SD) after PD-1/PD-L1 inhibitor treatment according to RECIST 1.1.
|
June 2020- June 2023 (3 year)
|
|
Time to Treatment Failure (TFF)
Aikaikkuna: June 2020- June 2023 (3 year)
|
The time from the start of PD-1/PD-L1 inhibitor to the withdrawal of the trial.
The reasons for withdrawal include the patient's voluntary withdrawal, disease progression, adverse events and even deaths.
|
June 2020- June 2023 (3 year)
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Yhteistyökumppanit
Tutkijat
- Päätutkija: Yayi He, PhD, MD, Shanghai Pulmonary Hospital, Shanghai, China
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Odotettu)
Maanantai 1. kesäkuuta 2020
Ensisijainen valmistuminen (Odotettu)
Lauantai 31. joulukuuta 2022
Opintojen valmistuminen (Odotettu)
Keskiviikko 31. toukokuuta 2023
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Torstai 9. huhtikuuta 2020
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Maanantai 20. huhtikuuta 2020
Ensimmäinen Lähetetty (Todellinen)
Tiistai 21. huhtikuuta 2020
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Tiistai 21. huhtikuuta 2020
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Maanantai 20. huhtikuuta 2020
Viimeksi vahvistettu
Keskiviikko 1. huhtikuuta 2020
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- RNA-virusinfektiot
- Virussairaudet
- Infektiot
- Hengitysteiden infektiot
- Hengityselinten sairaudet
- Neoplasmat
- Keuhkosairaudet
- Neoplasmat sivustoittain
- Hengitysteiden kasvaimet
- Rintakehän kasvaimet
- Syöpä, bronkogeeninen
- Keuhkoputkien kasvaimet
- Orthomyxoviridae -infektiot
- Keuhkojen kasvaimet
- Karsinooma, ei-pienisoluinen keuhko
- Influenssa, ihminen
- Huumeiden fysiologiset vaikutukset
- Farmakologisen vaikutuksen molekyylimekanismit
- Antineoplastiset aineet
- Immunologiset tekijät
- Vasta-aineet
- Rokotteet
- Immunoglobuliinit
- Vasta-aineet, monoklonaaliset
- Antineoplastiset aineet, immunologiset
- Immuunijärjestelmän tarkistuspisteen estäjät
Muut tutkimustunnusnumerot
- TIV-NSCLC-PD1
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Päättämätön
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Ei
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .